X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (486) 486
index medicus (419) 419
middle aged (334) 334
aged (321) 321
hematology (314) 314
adult (301) 301
oncology (294) 294
female (291) 291
male (288) 288
article (249) 249
aged, 80 and over (216) 216
treatment outcome (192) 192
prognosis (154) 154
adolescent (143) 143
antineoplastic combined chemotherapy protocols - therapeutic use (140) 140
leukemia, myeloid, acute - drug therapy (134) 134
acute myeloid leukemia (129) 129
young adult (129) 129
hematology, oncology and palliative medicine (127) 127
leukemia (123) 123
cancer (118) 118
therapy (115) 115
chemotherapy (114) 114
abridged index medicus (113) 113
antineoplastic agents - therapeutic use (95) 95
remission induction (93) 93
leukemia, myeloid, acute - genetics (88) 88
acute myelogenous leukemia (87) 87
aml (87) 87
acute myeloid-leukemia (85) 85
hemic and lymphatic diseases (85) 85
survival analysis (82) 82
disease-free survival (81) 81
survival (76) 76
care and treatment (75) 75
leukemia, myeloid, acute - mortality (72) 72
mutation (72) 72
minimal residual disease (63) 63
recurrence (62) 62
survival rate (62) 62
myelodysplastic syndromes (60) 60
protein kinase inhibitors - therapeutic use (59) 59
research (59) 59
risk factors (59) 59
chronic myelogenous leukemia (57) 57
myelodysplastic syndrome (57) 57
cytarabine - administration & dosage (56) 56
retrospective studies (55) 55
cytarabine (54) 54
leukemia, myeloid, acute - pathology (54) 54
follow-up studies (53) 53
dasatinib (51) 51
myelodysplastic syndromes - drug therapy (50) 50
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (50) 50
antineoplastic combined chemotherapy protocols - adverse effects (47) 47
cytogenetics (46) 46
patients (46) 46
adult patients (45) 45
analysis (43) 43
imatinib mesylate (43) 43
patient outcomes (43) 43
drug administration schedule (42) 42
stem-cell transplantation (42) 42
transplantation (42) 42
antineoplastic agents - administration & dosage (41) 41
diagnosis (41) 41
imatinib (41) 41
relapse (41) 41
fms-like tyrosine kinase 3 - genetics (40) 40
leukemia, myeloid, acute - diagnosis (39) 39
myeloid leukemia (39) 39
philadelphia chromosome (38) 38
chronic myeloid leukemia (37) 37
decitabine (37) 37
stem cells (37) 37
acute lymphoblastic leukemia (36) 36
azacitidine - analogs & derivatives (36) 36
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (36) 36
internal tandem duplication (35) 35
leukemia, myeloid, acute - therapy (35) 35
clinical trials (34) 34
clinical trials and observations (34) 34
dose-response relationship, drug (34) 34
kaplan-meier estimate (34) 34
acute lymphoblastic-leukemia (33) 33
antineoplastic combined chemotherapy protocols - administration & dosage (33) 33
multivariate analysis (33) 33
remission (33) 33
tyrosine (33) 33
adults (32) 32
azacitidine (32) 32
combination (32) 32
mutations (32) 32
acute lymphocytic leukemia (31) 31
acute promyelocytic leukemia (31) 31
age factors (31) 31
hyper-cvad (31) 31
salvage therapy (31) 31
antineoplastic agents - adverse effects (30) 30
chronic myeloid-leukemia (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 05/2018, Volume 131, Issue 21, pp. 2277 - 2278
Journal Article
Hematology, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 22 - 27
Abstract Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia exemplifies how the addition of potent targeted agents, directed at the... 
Index Medicus
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S6 - S6
Journal Article
Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 12/2017, Volume 2017, Issue 1, pp. 22 - 27
Journal Article
Blood, ISSN 0006-4971, 01/2019, Volume 133, Issue 2, pp. 130 - 136
The introduction of agents targeted at specific molecular events is changing the treatment paradigms in a number of malignancies. Historically, we have relied... 
CHRONIC MYELOGENOUS LEUKEMIA | ADULT PATIENTS | ALLOGENEIC TRANSPLANTATION | INTENSITY CHEMOTHERAPY | HYPER-CVAD | CHEMOTHERAPY PLUS DASATINIB | ABL TYROSINE KINASE | TERM-FOLLOW-UP | PHASE-II | STEM-CELL TRANSPLANTATION | HEMATOLOGY
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S12 - S12
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S123 - S123
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2018, Volume 31, Issue 4, pp. 396 - 400
Journal Article
Oncology Times, ISSN 0276-2234, 05/2018, Volume 40, Issue 10, pp. 5 - 7
Journal Article
Leukemia Research, ISSN 0145-2126, 2013, Volume 37, Issue 11, pp. 1434 - 1435
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 403 - 411
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2017, Volume 177, Issue 4, pp. 543 - 556
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 100 - 111
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1547 - 1555
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2011, Volume 155, Issue 4, pp. 413 - 419
Journal Article
Journal of oncology practice, ISSN 1554-7477, 11/2018, Volume 14, Issue 11, pp. 663 - 664
Journal Article